CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alliance Pharmaceutical Corp. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alliance Pharmaceutical Corp.
3550 General Atomics Court
MS 02/606
Phone: (858) 779-1458p:858 779-1458 San Diego, CA  92121  United States Fax: (858) 410-5161f:858 410-5161

On 10/18/2013, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Alliance Pharmaceutical Corp. for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.

Business Summary
Alliance Pharmaceutical Corp. (Alliance) is a pharmaceutical research and development company focused on developing the product, Oxygent, an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients. The results from the previous Phase II and Phase III clinical studies were used to develop the rationale for a new protocol design without autologous blood-conserving procedures (ANH) used in the previous clinical studies. The efficacy of Oxygent in terms of drug activity, and the ability of Oxygent to enable patients to maintain physiologic stability safely at lower intraoperative hemoglobin (Hb) levels were demonstrated in both of the Phase II and Phase III studies.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20106/30/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Duane J.Roth 61 10/1/1989 1/1/1985
President, Chief Financial Officer, Chief Operating Officer B. JackDeFranco 66 2/13/2008 10/13/2005
Independent Director PedroCuatrecasas 75 8/1/1996 8/1/1996
3 additional Officers and Directors records available in full report.

Business Names
Business Name
MOLECULAR BIOSYSTEMS, INC.
PFC Therapeutics, LLC
Talco Pharmaceutical, Inc.

General Information
Number of Employees: 1 (As of 6/30/2008)
Outstanding Shares: 67,459,219 (As of 5/20/2010)
Shareholders: 800
Stock Exchange: OTC
Federal Tax Id: 141644018
Fax Number: (858) 410-5161
Email Address: corpcom@allp.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023